Article
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Cancer research - 1 Sept 2014
Watson Ian R, Li Liren, Cabeceiras Peter K, Mahdavi Mozhdeh, Gutschner Tony, Genovese Giannicola, Wang Guocan, Fang Zhuangna, Tepper James M, Stemke-Hale Katherine, Tsai Kenneth Y, Davies Michael A, Mills Gordon B, Chin Lynda
Abstract excerpt
Following mutations in BRAF and NRAS, the RAC1 c.85C>T single-nucleotide variant (SNV) encoding P29S amino acid change represents the next most frequently observed protein-coding hotspot mutation in melanoma. However, the biologic and clinical significance of the RAC1 P29S somatic mutation in approximately 4% to 9% of patients remains unclear. Here, we demonstrate that melanoma cell lines possessing the RAC1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.